ES2143466T3 - Preparacion de anticuerpos quimericos usando la estrategia pcr recombinante. - Google Patents

Preparacion de anticuerpos quimericos usando la estrategia pcr recombinante.

Info

Publication number
ES2143466T3
ES2143466T3 ES91919298T ES91919298T ES2143466T3 ES 2143466 T3 ES2143466 T3 ES 2143466T3 ES 91919298 T ES91919298 T ES 91919298T ES 91919298 T ES91919298 T ES 91919298T ES 2143466 T3 ES2143466 T3 ES 2143466T3
Authority
ES
Spain
Prior art keywords
cdr
primers
antibody
preparation
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919298T
Other languages
English (en)
Inventor
James Scott Crowe
Alan Peter Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2143466T3 publication Critical patent/ES2143466T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A UN METODO PARA LA PRODUCCION DE UN ANTICUERPO QUIMERICO EN QUE EL CDR DE UN PRIMER ANTICUERPO SE UNE ENTRE LAS REGIONES DE MARCO DE UN SEGUNDO ANTICUERPO. EL METODO SE LLEVA A CABO UTILIZANDO UNA PLANTILLA QUE CONSTA DE DOS REGIONES DE MARCO, AB Y CD, Y ENTRE ELLAS, EL CDR QUE VA A SER SUSTITUIDO POR UN CDR DONADOR. SE UTILIZAN IMPRIMADORES A Y B PARA AMPLIFICAR LA REGION DE MARCO CD. SIN EMBARGO, LOS IMPRIMADORES B Y C CONTIENEN TAMBIEN, EN SUS EXTREMOS 5'', UNA SECUENCIA ADICIONAL CORRESPONDIENTE A TODA O POR LO MENOS A PARTE DE LA SECUENCIA DEL CDR DONADOR. LOS IMPRIMADORES B Y C SE SOLAPAN ENTRE SI UNA LONGITUD SUFICIENTE COMO PARA PERMITIR LA FIJACION POR CALOR DE SUS EXTREMOS 5'' BAJO CONDICIONES QUE PERMITEN QUE SE LLEVE A CABO UNA REACCION EN CADENA DE LA POLIMERASA Y POR TANTO INCORPORAR TODA LA SECUENCIA DEL CDR DONADOR. LAS REGIONES AMPLIFICADAS AB Y CD PUEDEN PASAR POR UNA EXTENSION DE SOLAPAMIENTO DE UNION PARA LA PRODUCCION DEL PRODUCTO QUIMERICO EN UNASOLA REACCION.
ES91919298T 1990-10-10 1991-10-08 Preparacion de anticuerpos quimericos usando la estrategia pcr recombinante. Expired - Lifetime ES2143466T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022011A GB9022011D0 (en) 1990-10-10 1990-10-10 Chimaeric antibodies and their preparation

Publications (1)

Publication Number Publication Date
ES2143466T3 true ES2143466T3 (es) 2000-05-16

Family

ID=10683489

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919298T Expired - Lifetime ES2143466T3 (es) 1990-10-10 1991-10-08 Preparacion de anticuerpos quimericos usando la estrategia pcr recombinante.

Country Status (9)

Country Link
US (1) US5858725A (es)
EP (1) EP0552266B1 (es)
JP (1) JP3516950B2 (es)
AT (1) ATE188995T1 (es)
DE (1) DE69131930T2 (es)
DK (1) DK0552266T3 (es)
ES (1) ES2143466T3 (es)
GB (1) GB9022011D0 (es)
WO (1) WO1992007075A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
JP4157160B2 (ja) * 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US20060257890A1 (en) * 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6309883B1 (en) * 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
GB9712512D0 (en) 1997-06-16 1997-08-20 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
JP2001518310A (ja) * 1997-09-29 2001-10-16 シティ・オブ・ホープ 核酸断片の効率的連結
IL136574A0 (en) * 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
BR9906927A (pt) * 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
WO2001007082A1 (en) 1999-07-23 2001-02-01 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US20040005709A1 (en) * 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
AU2003230027A1 (en) * 2002-05-17 2003-12-02 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
CN102174533A (zh) 2002-10-15 2011-09-07 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
EP2759307B1 (en) 2006-03-29 2016-11-09 Merial Limited Vaccine against Streptococci
WO2009039584A1 (en) 2007-09-28 2009-04-02 Welcome Receptor Antibodies Pty Ltd Diagnosis and treatment of diseased and damaged tissue
ES2883176T3 (es) 2007-11-08 2021-12-07 Prec Biologics Inc Anticuerpos monoclonales recombinantes y antígenos correspondientes para cánceres de colon y de páncreas
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
ES2542744T3 (es) * 2009-12-17 2015-08-11 Novimmune Sa Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural
US9361427B2 (en) * 2011-02-01 2016-06-07 The Regents Of The University Of California Scar-less multi-part DNA assembly design automation
DK2888283T3 (en) 2012-08-24 2018-11-19 Univ California ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE
EP3169343B1 (en) 2014-07-15 2020-03-25 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Isolated polypeptides of cd44 and uses thereof
JP7109007B2 (ja) 2016-06-27 2022-07-29 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア がん治療の組み合わせ
KR20220147684A (ko) * 2017-05-10 2022-11-03 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 최적화된 핵산 항체 작제물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same

Also Published As

Publication number Publication date
JP3516950B2 (ja) 2004-04-05
DE69131930D1 (de) 2000-02-24
EP0552266B1 (en) 2000-01-19
ATE188995T1 (de) 2000-02-15
JPH06501614A (ja) 1994-02-24
EP0552266A1 (en) 1993-07-28
DE69131930T2 (de) 2000-08-03
GB9022011D0 (en) 1990-11-21
WO1992007075A1 (en) 1992-04-30
DK0552266T3 (da) 2000-06-26
US5858725A (en) 1999-01-12

Similar Documents

Publication Publication Date Title
ES2143466T3 (es) Preparacion de anticuerpos quimericos usando la estrategia pcr recombinante.
DK0866071T3 (da) Modificerede primere
ES2128323T3 (es) Reduccion de la amplificacion no-especifica durante la amplificacion in vitro del acido nucleico empleando bases de acido nucleico modificadas.
ES2103819T3 (es) Metodo para el diagnostico del virus del papiloma humano tipo 16 utilizando la reaccion en cadena de la polimerasa.
NO872757D0 (no) Alkynylaminonukleotider og fremgangsmaate for fremstilling av disse.
ES2052591T3 (es) Variantes de virus lav, sus componentes de adn y de proteinas, y sus utilizaciones particularmente con fines diagnosticos y para la preparacion de composiciones inmunogenicas.
DE3854956D1 (de) Nukleinsäuremultimere und amplifizierte Nukleinsäurehybridisierungstests damit
ES2104722T3 (es) Composiciones terapeuticas a base de ribozimas.
ES2156978T3 (es) Uso de exonucleasa y/o glicosilasa como suplementos de un anticuerpo antipolimerasa para aumentar la especifidad en la reaccion en cadena de la polimerasa.
ATE312942T1 (de) Amplifizierung unter verwendung von modifizierten primern
DK0887427T3 (da) Amplifikation og detektion af HIV-1 og/eller HIV-2
FR2391990A1 (fr) Procede pour la preparation de fluorobenzenes par reaction de chlorobenzenes avec le fluorure de potassium
ES2114525T3 (es) Uso de cebadores oligonucleotidicos conservados para la amplificacion de las secuencias de adn del virus de papiloma humano.
ES2094178T3 (es) Secuencias nucleotidicas utiles como sondas especificas del tipo cebadores pct y sondas para la amplificacion y deteccion del virus del papiloma humano, y kits y procedimientos utilizados con este fin.
MX172198B (es) Mejoras en reactor y procesos de reaccion en un lecho fluidificado con etapas multiples
ES498476A0 (es) Procedimiento de preparacion de arn ribosomales bacterianos
ES2059577T3 (es) Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion.
DK177785A (da) Fremgangsmaade til fluorescensslukning og kationiske eller amfotere aromatiske nitroforbindelser
DE69132044D1 (de) Markierte, modifizierte Oligonokleotiden
FI833101A (fi) Substituerade tert. -butanol-derivat, foerfarande foer deras framstaellning och dessa innehaollandeantimykotiska medel
ES2067514T3 (es) Secuencia de adn de solanum tuberosum estimulada por vulneracion, y su empleo.
ATE85186T1 (de) Verschmolzenes biologisches bekaempfungsmittel.
EP1317032A3 (de) Pumpquelle mit mehreren Pumplasern zur Raman-Verstärkung eines WDM-Signals mit minimierter Vierwellenmischung
CLARK et al. Q fever in California
SU175238A1 (ru) Ферритная сталь

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552266

Country of ref document: ES